Custom Tailoring Therapy for Breast Cancer Using erbB-2
Final rept. 15 Dec 92-14 Dec 94
GEORGETOWN UNIV WASHINGTON DC
Pagination or Media Count:
In order to examine the role of erbB-2 as a therapeutic response variable in breast cancer, 937 cases from NSABP B-l4 and 207 cases from NSABP B-11 were examined using immunohistochemical assay. Both studies failed to demonstrate the value of erbB-2 in predicting response to specific treatment regimens used in the studies tamoxifen or adriamycin. In order to clone additional therapeutic response variables that may predict response to tamoxifen, we have used gene trap approach. A novel estrogen suppressed gene was partially cloned. in addition, we were able to confirm estrogen regulation of bcl-2 gene, which could be a potential predictor of tamoxifen response.
- Medicine and Medical Research